Clik here to view.
PMC Group International Announces Acquisition of Pharma Company in France
MOUNT LAUREL, N.J. PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of the pharma business of...
View ArticleClik here to view.
Clik here to view.
PMC Group International宣布收购法国制药公司
新泽西州芒特劳雷尔 (美国商业资讯) — PMC Group Inc.的独立分支机构PMC Group International Inc.旗下的全资子公司PMC Group France宣布收购法国Isochem...
View ArticleClik here to view.
Orthocell Commences Treatment of Its 1,000th Patient
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce that it has commenced treatment of its 1,000th patient, in its TGA...
View ArticleClik here to view.
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3...
View ArticleClik here to view.
ベルタンとザイモリサーチが新しい連携を発表
米カリフォルニア州アーバイン & メリーランド州ロックビル （ビジネスワイヤ） — ザイモリサーチ・コープとベルタンは、マイクロバイオームワークフローにおけるサンプル溶解処置を完全でバイアスのないものとする連携を発表します。ZymoBIOMICS®微生物叢標準品およびDNA精製用ZymoBIOMICS...
View ArticleClik here to view.
Bertin与Zymo Research宣布达成新的合作
加州尔湾和马里兰州罗克韦尔 (美国商业资讯) — Zymo Research Corp.与Bertin宣布一项合作，共同确保微生物圈工作流程中的样品溶解步骤完整无偏差。一份应用备注已经发布，其描述了材料、步骤和采用Precellys® Evolution...
View ArticleClik here to view.
ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu...
LAUSANNE, Schweiz ADC Therapeutics (ADCT), ein onkologisches Biotech-Unternehmen, das sich auf die Entwicklung von geschützten Antikörper-Wirkstoff-Konjugaten (Antibody Drug Conjugates, ADCs) zur...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-301（camidanlumab...
View ArticleClik here to view.
武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据，该试验评估ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) – 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验的数据将于2017年12月10日星期天在第59届美国血液学会(ASH)年会的全体科学会议上呈报，该项试验评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with...
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research...
View ArticleClik here to view.
ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、リンパ腫と白血病の重要な亜型でADCT-402（loncastuximab...
View ArticleClik here to view.
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for...
PRINCETON, N.J. & OSAKA, Japan Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “Ono”) announced an...
View ArticleClik here to view.
Corindus Announces First Commercial Installation of CorPath® GRX System...
WALTHAM, Mass. Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System...
View ArticleClik here to view.
Orthocell Granted European Tendon Regeneration Patent
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled...
View ArticleClik here to view.
Chi-Med Initiates Fruquintinib U.S. Clinical Trials
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...
View ArticleClik here to view.
Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho...
NEW YORK Eternity Healthcare (“Eternity” or the “Company”) (OTC: ETAH) today announced that it has entered into a share exchange agreement (the “Exchange Agreement”) dated December 13, 2017, with...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスが進行期ホジキンリンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を評価する第3相ECHELON-...
米マサチューセッツ州ケンブリッジ & 大阪 & ワシントン州ボセル （ビジネスワイヤ）– 武田薬品工業株式会社（TSE:4502）とシアトル・ジェネティクス（NASDAQ:...
View ArticleClik here to view.
Dr. Reddy’s announces it has reached a settlement with the US Government...
HYDERABAD, India & PRINCETON, N.J. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)—The US subsidiary of Dr. Reddy’s Laboratories Ltd. announced today that it has reached a settlement with the US...
View ArticleClik here to view.
Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View Article